On Monday night, Senators Mike Lee (R-Utah) and Jerry Moran (R-Kansas) announced their opposition to the Republican healthcare reform bill, the Better Care Reconciliation Act (BCRA).
On Monday night, Senators Mike Lee (R-Utah) and Jerry Moran (R-Kansas) announced their opposition to the Republican healthcare reform bill, the Better Care Reconciliation Act (BCRA). Senators Lee and Moran joined Senators Rand Paul (R-Kentucky) and Susan Collins (R-Maine) in saying that they would not support the bill, leaving Senate Majority Leader Mitch McConnell 2 votes short of the number needed to pass the act. This final blow to the BCRA comes after a vote on the bill was delayed in order to allow Senator John McCain (R-Arizona) to recover after undergoing surgery last week.
In his formal announcement of his opposition to the bill, Senator Moran said, “There are serious problems with Obamacare, and my goal remains what it has been for a long time: to repeal and replace it. This closed-door process has yielded the BCRA, which fails to repeal the Affordable Care Act (ACA) or address healthcare’s rising costs. For the same reasons I could not support the previous version of this bill, I cannot support this one.” Senator Lee said in his own statement that he could not vote in favor of the act because it “doesn’t go far enough in lowering premiums for middle class families; nor does it create enough free space from the most costly Obamacare regulations.”
Senator McConnell said that “the effort to repeal and immediately replace the failure of Obamacare will not be successful,” and added that Republicans now plan to repeal the ACA without immediately proposing new legislation to take its place. Such a move could have cascading consequences for the biosimilars industry; the Biologics Price Competition and Innovation Act, which established an accelerated approval pathway for biosimilar products, was passed into law as part of the ACA. The Washington Post reports, however, that many centrist Republican lawmakers are opposed to a straight repeal of the Obama-era legislation, and that such a repeal would be unlikely to pass.
The uncertain future of Republican healthcare reform has created an opportunity for the FDA Reauthorization Act, passed by the House last week, to reach a vote more quickly. Senator McConnell placed the FDARA on the Senate’s calendar on Monday, moving the bipartisan bill a step closer to its expected passage. While McConnell has not yet disclosed a date for a Senate vote on the FDARA, some have suggested that the failure of the BCRA could allow lawmakers time to vote on the reauthorization plan for user fees sooner rather than later.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
April 3rd 2024Although tender systems are a common strategy to encourage biosimilar utilization across Europe, policies like automatic substitution are rarely utilized, according to a systematic review of European policies and biosimilar uptake.